Curon Stretta
This article was originally published in The Gray Sheet
Executive Summary
Voluntary recall of all affected lots of the catheters for treatment of gastroesophageal reflux disease (GERD) is complete, Curon announces Jan. 5. A "manufacturing irregularity" related to 278 catheters "has been identified, and we have resumed normal manufacturing processes," Curon says. The firm does not expect "a major impact" on 2001 fiscal year results, according to President and CEO John Morgan. The device received 510(k) clearance in April (1"The Gray Sheet" Oct. 2, 2000, p. 16)
You may also be interested in...
Curon To Beef Up Sales Force For Stretta GERD System With $55 Mil. IPO
Curon Medical will use $2 mil. of its $55 mil. initial public offering for sales and marketing initiatives related to its recently launched Stretta radiofrequency system for gastroesophageal reflux disease (GERD), according to a Sept. 22 IPO prospectus filed with the Securities and Exchange Commission.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.